| Dermatitis |
NCT05870865: A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis |
|
|
| Completed | 2 | 131 | US | ASN008, ASN008 Matching Vehicle | TrialSpark | Dermatitis, Atopic, Pruritus | 11/23 | 12/23 | | |
NCT05509023: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) |
|
|
| Recruiting | 2 | 102 | US | ADX-914, Placebo | Q32 Bio Inc. | Atopic Dermatitis | 12/24 | 12/24 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
NCT06176040: A Study of TAVO101 in Atopic Dermatitis Patients |
|
|
| Recruiting | 2 | 20 | RoW | TAVO101 | Tavotek Biotherapeutics | Atopic Dermatitis | 10/24 | 01/25 | | |
NCT05671445: The Study of CM326 in Adult Subjects With Atopic Dermatitis |
|
|
| Recruiting | 2 | 100 | RoW | CM326 | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 03/24 | 03/25 | | |
NCT05715320: Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | CM310 | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 03/24 | 03/24 | | |
NCT06363461: Study of TDM-180935 in Atopic Dermatitis Patients |
|
|
| Recruiting | 2 | 24 | US | TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1, TDM-180935 topical vehicle ointment 2 | Technoderma Medicines Inc., Therapeutics, Inc. | Atopic Dermatitis | 09/24 | 10/24 | | |
| Recruiting | 2 | 471 | Canada, US | APG777, Placebo | Apogee Therapeutics, Inc. | Atopic Dermatitis | 11/26 | 06/28 | | |
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 60 | Canada, US | Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo | Apollo Therapeutics Ltd | Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic | 02/25 | 06/25 | | |
NCT04325802: Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone |
|
|
| Withdrawn | 2 | 56 | US | Naltrexone, Placebo | University of Minnesota | Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis | 06/24 | 06/24 | | |
| Not yet recruiting | 2 | 158 | Europe, Canada, Japan, US, RoW | GSK1070806 | GlaxoSmithKline | Dermatitis, Atopic | 11/29 | 11/29 | | |
NCT06309355: Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis |
|
|
| Recruiting | 2 | 36 | US | YR001 ointment, Placebo | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Atopic Dermatitis | 01/25 | 06/25 | | |
NCT05905133: A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD |
|
|
| Active, not recruiting | 2 | 360 | RoW | CBP-201, CBP-201 injection | Suzhou Connect Biopharmaceuticals, Ltd. | Atopic Dermatitis | 06/24 | 06/24 | | |
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis |
|
|
| Terminated | 2 | 229 | Canada, US | RPT193, Placebo | RAPT Therapeutics, Inc. | Atopic Dermatitis | 05/24 | 05/24 | | |
NCT06397911: Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 90 | NA | FB825, Placebo | Oneness Biotech Co., Ltd. | Atopic Dermatitis | 12/26 | 12/26 | | |
NCT04246372: Tofacitinib for Immune Skin Conditions in Down Syndrome |
|
|
| Recruiting | 2 | 47 | US | Tofacitinib, Xeljanz | University of Colorado, Denver, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis | 08/24 | 12/24 | | |
NCT05388760 / 2021-005573-12: Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) |
|
|
| Active, not recruiting | 2 | 24 | Europe, RoW | Tralokinumab | LEO Pharma | Atopic Dermatitis | 10/23 | 04/26 | | |
ChiCTR2200063605: A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QX005N injection in adult subjects with moderate to severe atopic dermatitis (phase II) |
|
|
| Not yet recruiting | 2 | 120 | | QX005N 300mg ;QX005N 600mg ;placebo | Peking Union Medical College Hospital; Qyuns Therapeutics Co., Ltd., Qyuns Therapeutics Co., Ltd. | Moderate to severe atopic dermatitis | | | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 260 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 09/24 | 05/25 | | |
NCT06058000: A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 120 | RoW | 1.5% QLM3003, 2% QLM3003, Vehicle (Placebo) | Qilu Pharmaceutical Co., Ltd. | Atopic Dermatitis | 10/24 | 12/24 | | |
NCT06101823: Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 48 | Canada, US | OpSCF, Placebo, OpSCF (Open Label Extension) | Opsidio, LLC, Innovaderm Research Inc. | Atopic Dermatitis | 10/24 | 06/25 | | |
NCT06092762: A Phase II Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 180 | RoW | AK120 | Akeso | Atopic Dermatitis | 10/24 | 05/25 | | |
NCT05935085: This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD). |
|
|
| Recruiting | 2 | 160 | Europe, Canada, US, RoW | ANB032, Placebo | AnaptysBio, Inc. | Atopic Dermatitis Eczema | 11/24 | 01/25 | | |
ADAMANT, NCT05932654: POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis |
|
|
| Recruiting | 2 | 80 | US | BSI-045B, Dupilumab, Dupixent | Biosion, Inc. | Atopic Dermatitis | 11/24 | 11/24 | | |
| Terminated | 2 | 103 | US | BMX-010, Placebo | BioMimetix JV, LLC, Innovaderm Research Inc. | Atopic Dermatitis | 12/23 | 04/24 | | |
NCT04307862: Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis |
|
|
| Recruiting | 2 | 165 | RoW | ZEP-3Na 0.1%, ZEP-3Na 1%, Placebo Vehicle only | Shulov Innovate for Science Ltd. 2012 | Atopic Dermatitis | 12/24 | 02/25 | | |
NCT05717920: A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) |
|
|
| Recruiting | 2 | 10 | US | Part 1 ADX-629 (Open-label) | Aldeyra Therapeutics, Inc. | Atopic Dermatitis | 12/24 | 12/24 | | |
NCT05923099: A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | LEO 138559, Placebo | LEO Pharma | Atopic Dermatitis | 12/24 | 03/25 | | |
NCT06013371: PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea |
|
|
| Recruiting | 2 | 66 | US | PF-07038124, Placebo Ointment | Icahn School of Medicine at Mount Sinai, Pfizer | Seborrheic Dermatitis, Papulopustular Rosacea | 12/24 | 12/24 | | |
NCT04921345: Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 105 | Europe, US | Nemolizumab, CD14152 | Galderma R&D | Moderate-to-Severe Atopic Dermatitis | 01/25 | 07/25 | | |
|
| Active, not recruiting | 2 | 238 | US, RoW | Placebo, SCD-044_Dose 1, SCD-044_Dose 2, SCD-044_Dose 3 | Sun Pharmaceutical Industries Limited | Dermatitis, Atopic | 01/25 | 06/25 | | |
ADVANTA, NCT06058156: Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 115 | Europe, US | SAR444656 (KT-474), Placebo | Sanofi, Kymera Therapeutics, Inc. | Atopic Dermatitis | 01/25 | 02/25 | | |
HYDRO, NCT06015308: A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo |
|
|
| Recruiting | 2 | 166 | Canada, US | Amlitelimab, Placebo, Tdap vaccine, PPS vaccine | Sanofi | Dermatitis Atopic | 04/25 | 08/25 | | |
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 175 | Europe, Canada, Japan, US, RoW | GSK1070806, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 04/25 | 06/25 | | |
NCT06012812: A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 2 | 240 | RoW | SHR-1819 injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Moderate to Severe Atopic Dermatitis | 05/25 | 05/25 | | |
NCT05607901: A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone |
|
|
| Recruiting | 2 | 100 | RoW | Tacrolimus ointment, Hydrocortisone 1% cream | Tanta University | Dermatologic Disease | 06/25 | 08/25 | | |
NCT06096857: Cardamom and Topical Roseomonas in Atopic Dermatitis |
|
|
| Recruiting | 2 | 240 | US | Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose) | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis, Eczema | 01/26 | 01/26 | | |
NCT06024499: Phase 2 Trial of HY209gel in Atopic Dermatitis Patients |
|
|
| Recruiting | 2 | 210 | US | HY209GEL Active, Placebo | Shaperon | Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp | 10/25 | 03/26 | | |
NCT05505214: Topical Steroids & Bacterial Decolonization for Radiation Dermatitis |
|
|
| Withdrawn | 2 | 216 | US | Bacterial decolonization, Mometasone furoate 0.1% cream, Bacterial decolonization and Mometasone furoate 0.1% cream | Montefiore Medical Center | Radiation Dermatitis | 09/25 | 09/25 | | |
NCT06116565: A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 300 | NA | CM310 | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 03/26 | 03/26 | | |
NCT05995964: A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 340 | Canada, Japan, US | PF-07275315, PF-07264660, Placebo | Pfizer | Atopic Dermatitis | 02/26 | 02/26 | | |
| Recruiting | 2 | 312 | Europe, US | Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care | Kari Nadeau, MD, PhD, King's College London and Guy's & St. Thomas Hospital, National Jewish Health, University of Chicago, Children's Hospital Medical Center, Cincinnati, Harvard School of Public Health (HSPH), Stanford University | Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis | 05/27 | 06/27 | | |
NCT05997927: Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 152 | RoW | VC005 tablets, VC005 Tablets Placebo | Jiangsu vcare pharmaceutical technology co., LTD | Moderate to Severe Atopic Dermatitis | 08/26 | 08/26 | | |
NCT05190770: A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer |
|
|
| Recruiting | 2 | 50 | US | Triamcinolone Acetonide, Oleogel-S10 | Memorial Sloan Kettering Cancer Center | Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV | 12/26 | 12/26 | | |
NCT04865731: Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer |
|
|
| Recruiting | 2 | 45 | US | Dermaprazole, esomeprazole, Aquaphor | The University of Texas Health Science Center at San Antonio | Cancer of the Head and Neck | 09/27 | 09/28 | | |
| Recruiting | 2 | 450 | Europe, Canada, Japan, US, RoW | Amlitelimab, SAR445229, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids | Sanofi, Sanofi-aventis recherche & développement | Dermatitis Atopic | 10/27 | 04/28 | | |
ATLANTIS, NCT05769777: Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 901 | Europe, Canada, Japan, RoW | Amlitelimab | Sanofi | Dermatitis Atopic | 10/28 | 10/28 | | |
NCT03835767: Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis |
|
|
| Recruiting | 2 | 200 | US | Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | Milk and/or Peanut Allergy | 12/27 | 12/27 | | |
NCT05240300: A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 1b/2a | 48 | NA | BX005-A, Placebo | BiomX, Inc., Maruho Co., Ltd. | Atopic Dermatitis | 06/23 | 06/23 | | |
ACTRN12605000403639: A Phase 1/2 Multicenter, Randomized, Placebo-Controlled Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Two Regimens of a Candidate Topical NF kappaB Decoy in the Treatment of Adults with Mild to Moderate Atopic Dermatitis |
|
|
| Recruiting | 1/2 | 120 | | | Corgentech Inc., Corgentech Inc. | Atopic dermatitis | | | | |
2009-014582-51: Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels |
|
|
| Ongoing | 1/2 | 10 | Europe | Xolair, Xolair-H-C-606-II-18, Omalizumab, Omalizumab | Faculty of Medicine, Technische Universität München | Patients with severe Atopic dermatitis and total IgE-level > 700 IU/ml (potentially associated with bronchial asthma and/or allergic rhinitis) | | | | |
2016-000376-26: A study to determine the effects of up to 2 weeks of treatment with an ointment applied to the skin containing the drug ZPL-5212372 in healthy volunteers and adult patients with moderate to severe atopic dermatitis. |
|
|
| Ongoing | 1/2 | 54 | Europe | ZPL-5212372, Ointment | Ziarco Pharma Ltd, Ziarco Pharma Ltd | Atopic Dermatitis, Atopic Dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-003639-41: A study to test the safety, pharmacokinetics and efficacy of UCB9741 in healthy study participants and in study participants with atopic dermatitis |
|
|
| Not yet recruiting | 1/2 | 159 | Europe | UCB9741, Solution for injection/infusion | UCB Biopharma SRL, UCB Biopharma SRL | Atopic Dermatitis, Atopic Dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT03830177: Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult |
|
|
| Recruiting | 1/2 | 60 | US | Natural Treatment | Ann & Robert H Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University | Dermatitis, Seborrheic, Dry Skin; Eczema | 08/22 | 08/22 | | |
NCT04179760: Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 1/2 | 92 | RoW | SCM-AGH, Placebo | SCM Lifescience Co., LTD. | Dermatitis, Atopic | 08/22 | 10/22 | | |
NCT04220411: A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD) |
|
|
| Terminated | 1/2 | 17 | RoW | AR100DP1 | Arjil Pharmaceuticals LLC | Dermatitis, Atopic | 12/21 | 06/22 | | |
NCT05186922: The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 1/2 | 54 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 01/23 | 01/23 | | |
| Completed | 1/2 | 123 | Europe | BEN2293 (0.25% or 1.0% w/w) or matching placebo, BEN2293 | BenevolentAI Bio, BenevolentAI Bio Limited | Atopic Dermatitis | 01/23 | 01/23 | | |
NCT04725136: Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis |
|
|
| Recruiting | 1/2 | 96 | RoW | FURESTEM-AD inj | Kang Stem Biotech Co., Ltd. | Atopic Dermatitis | 01/23 | 05/23 | | |
NCT05487963: Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis |
|
|
| Not yet recruiting | 1/2 | 40 | NA | Tofacitinib Citrate, placebo ointment | CAGE Bio Inc. | Atopic Dermatitis | 03/23 | 04/23 | | |
NCT04313400: Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis |
|
|
| Completed | 1/2 | 91 | US | 1.1% w/w AMTX-100 CF-part1, Placebo, placebo (vehicle 0% w/w), 1.1% w/w AMTX-100 CF3-part2, part2 | Amytrx Therapeutics, Inc., Amarex Clinical Research | Atopic Dermatitis | 12/23 | 01/24 | | |
NCT04435392: Jaktinib Hydrochloride Cream For Atopic Dermatitis |
|
|
| Completed | 1/2 | 107 | RoW | Jaktinib Hydrochloride Cream, Jaktinib, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 09/22 | 09/22 | | |
NCT05613062: Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children |
|
|
| Recruiting | 1/2 | 20 | RoW | Modified Huang-Lian-Jie-Du Decoction (MHLJDD), Chinese medicine, Placebo | Chinese University of Hong Kong | Atopic Dermatitis | 12/23 | 06/24 | | |
| Active, not recruiting | 1/2 | 20 | US | Ruxolitinib | University of Rochester, Incyte Corporation | Chronic Hand Dermatitis | 06/23 | 12/24 | | |
ChiCTR2100051917: Randomized, double-blind, placebo-controlled tolerability, safety, pharmacokinetics and preliminary efficacy on Ib/II clinical trail of GR1802 injection in patients with moderate and severe atopic dermatitis by multiple subcutaneous injections |
|
|
| Not yet recruiting | 1/2 | 150 | | GR1802 injection ;Placebo | Huashan Hospital Affiliated to Fudan University; Genrix (Shanghai) Pharmaceutical Technology Co., Ltd, Self-financed | Atopic Dermatitis | | | | |
NCT04617730: Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold. |
|
|
| Not yet recruiting | 1/2 | 35 | NA | Mepitel® film, Flamigel® | Jules Bordet Institute | Radiodermatitis, Radiation Toxicity, Radiotherapy Side Effect | 01/24 | 01/25 | | |
NCT06324812: Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 1/2 | 104 | NA | Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 08/24 | 08/24 | | |
NCT06162507: Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis |
|
|
| Not yet recruiting | 1/2 | 24 | NA | CM310 | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 03/25 | 03/25 | | |
NCT04369846: A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients |
|
|
| Recruiting | 1/2 | 102 | RoW | GM-XANTHO onitment, Drawing blood, Placebo onitment | Xantho Biotechnology Co., LTD, Virginia Contract Research Organization Co., Ltd. | Atopic Dermatitis | 06/24 | 12/24 | | |
| Active, not recruiting | 1/2 | 264 | US, RoW | STMC-103H, Placebo | Siolta Therapeutics, Inc. | Atopic Dermatitis, Type 1 Hypersensitivity | 11/24 | 10/25 | | |
NCT06035354: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis |
|
|
| Recruiting | 1/2 | 416 | RoW | AK120, Placebo | Akeso | Atopic Dermatitis | 09/24 | 10/24 | | |
TOPAZ, NCT05269160: Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients |
|
|
| Recruiting | 1/2 | 57 | US | Dermaprazole 1%, Dermaprazole 2% | Michelle S Ludwig | Radiation Dermatitis, Breast Cancer, Head and Neck Cancer | 01/25 | 01/27 | | |
NCT05277571: A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) |
|
|
| Recruiting | 1/2 | 152 | US | UCB1381, Placebo | UCB Biopharma SRL | Atopic Dermatitis | 01/25 | 01/25 | | |
NCT05984784: A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) |
|
|
| Terminated | 1/2 | 13 | Canada, US | Placebo, IMG-007 | Inmagene LLC | Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD | 04/24 | 04/24 | | |
| Recruiting | 1/2 | 126 | RoW | Monoclonal antibody BAT6026, BAT6026, sodium chloride injection | Bio-Thera Solutions | Dermatitis, Atopic | 02/25 | 10/25 | | |
NCT05525715: A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 1/2 | 260 | NA | 2mg QY201 tablets or 2mg QY201 placebo,BID, 5mg QY201 tablets or 5mg QY201 placebo,BID, 10mg QY201 tablets or 10mg QY201 placebo,QD, 10mg QY201 tablets or 10mg QY201 placebo,BID, 15mg QY201 tablets or 15mg QY201 placebo,BID, 20mg QY201 tablets or 20mg QY201 placebo,BID, 5mg QY201 tablets，BID, 10mg QY201 tablets，BID, 20mg QY201 tablets，BID, QY201 placebo，BID | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Atopic Dermatitis | 12/25 | 12/25 | | |
